Publication date: Oct 13, 2024
Hypomimia is a non-motor symptom of Parkinson’s disease that manifests as delayed facial movements and expressions, along with challenges in articulation and emotion. Currently, subjective evaluation by neurologists is the primary method for hypomimia detection, and conventional rehabilitation approaches heavily rely on verbal prompts from rehabilitation physicians. There remains a deficiency in accessible, user-friendly and scientifically rigorous assistive tools for hypomimia treatments. To investigate this, we developed HypomimaCoach, an Action Unit (AU)-based digital therapy system for hypomimia detection and rehabilitation in Parkinson’s disease. The HypomimaCoach system was designed to facilitate engagement through the incorporation of both relaxed and controlled rehabilitation exercises, while also stimulating initiative through the integration of digital therapies that incorporated traditional face training methods. We extract action unit(AU) features and their relationship for hypomimia detection. In order to facilitate rehabilitation, a series of training programmes have been devised based on the Action Units (AUs) and patients are provided with real-time feedback through an additional AU recognition model, which guides them through their training routines. A pilot study was conducted with seven participants in China, all of whom exhibited symptoms of Parkinson’s disease hypomimia. The results of the pilot study demonstrated a positive impact on participants’ self-efficacy, with favourable feedback received. Furthermore, physician evaluations validated the system’s applicability in a therapeutic setting for patients with Parkinson’s disease, as well as its potential value in clinical applications.
Concepts | Keywords |
---|---|
Italy | Aus |
Melodious | Based |
Neurologists | Detection |
Pilot | Digital |
Facial | |
Feedback | |
Hypomimia | |
Movements | |
Parkinson | |
Participants | |
Rehabilitation | |
System | |
Therapy | |
Training |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | Parkinson’s Disease |
drug | DRUGBANK | Carboxyamidotriazole |
drug | DRUGBANK | Coenzyme M |
drug | DRUGBANK | Trestolone |
disease | MESH | neurological disorder |
disease | MESH | facial expression |
disease | MESH | dysarthria |
disease | MESH | depression |
disease | MESH | cognitive impairment |
disease | MESH | anxiety |
drug | DRUGBANK | Tretamine |
disease | MESH | sleep quality |
disease | MESH | paralysis |
disease | MESH | neuritis |
disease | MESH | tic |
disease | MESH | facial paralysis |
disease | MESH | mood disorders |
drug | DRUGBANK | Trihexyphenidyl |
drug | DRUGBANK | Profenamine |
disease | MESH | speech disorders |
drug | DRUGBANK | Pentaerythritol tetranitrate |
disease | MESH | emotional disturbances |
disease | MESH | hypomania |
drug | DRUGBANK | Flunarizine |
disease | MESH | privacy |
drug | DRUGBANK | Spinosad |
drug | DRUGBANK | Tropicamide |